Navigation Links
PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
Date:5/4/2010

ANNAPOLIS, Md., May 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Interim CEO, Eric I. Richman, will be participating on a special biosecurity panel presentation promoting the critical interrelationship between government, academia and industry in the development of medical countermeasures vital to our nation's biosecurity.

The panel presentation, entitled "Public Private Partnerships for State-of-the-Art Countermeasures" will be held at 4:00 pm EDT on Wednesday, May 5, 2010, as part of the inaugural 2010 Biosecurity Conference, co-located with the 2010 BIO International Conference, May 3-6, 2010, McCormick Place, Chicago, IL.  

Officials in the biodefense industry note that increasing our nation's capability to rapidly and effectively develop and produce new and better medical countermeasures might not simply prevent casualties, but reduce the likelihood of such an attack.  Panelists, which include senior government officials and leading industry representatives will assess the process for the creation of these countermeasures and analyze the successes and challenges in their development through case studies and discussion, with the goal of enhancing our biodefense readiness and strategic national arsenal.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
2. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
3. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
4. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
5. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
8. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
9. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
10. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
11. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... PA (PRWEB) , ... May 19, 2017 , ... ... its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and ... New Jersey and Delaware, are encouraged to submit proposals. QED, now in its ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, ... of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, ... Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY ... industries, including food and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, ... of use. The improvement in technology comes on the heels of HOLLOWAY’s release ...
(Date:5/16/2017)... ... May 16, 2017 , ... Genedata, a leading ... Screener User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, ... practices in screening data analysis and learn about the latest advances in screening ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):